Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Samaison

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Human Pathology|May 21, 2021
MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratoriesClaire Bocciarelli, Charline Caumont, Laura Samaison, et al.
Genes, Chromosomes & Cancer|December 21, 2016
Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcomeDamien Luque Paz, Aurélie Chauveau, Françoise Boyer, et al.
Journal of Clinical Pathology|April 11, 2020
Evaluation of <i>KRAS</i>, <i>NRAS</i> and <i>BRAF</i> mutational status and microsatellite instability in early colorectal carcinomas invading the <i>submucosa</i> (pT1): towards an in-house molecular prognostication for pathologists?Amélie Bourhis, Caterina De Luca, Mélanie Cariou, et al.
Pathology|November 28, 2018
High reproducibility is attainable in assessing histoprognostic parameters of pT1 colorectal cancer using routine histopathology slides and immunohistochemistry analysesFanny Barel, Anaïs Auffret, Mélanie Cariou, et al.
Scientific Reports|June 8, 2019
Histopathological factors help to predict lymph node metastases more efficiently than extra-nodal recurrences in submucosa invading pT1 colorectal cancerFanny Barel, Mélanie Cariou, Philippe Saliou, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell LymphomaVincent Rebière, Meriem Maajem, Ronan Le Calloch, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Human Pathology|May 21, 2021
MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratoriesClaire Bocciarelli, Charline Caumont, Laura Samaison, et al.
Genes, Chromosomes & Cancer|December 21, 2016
Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcomeDamien Luque Paz, Aurélie Chauveau, Françoise Boyer, et al.
Journal of Clinical Pathology|April 11, 2020
Evaluation of <i>KRAS</i>, <i>NRAS</i> and <i>BRAF</i> mutational status and microsatellite instability in early colorectal carcinomas invading the <i>submucosa</i> (pT1): towards an in-house molecular prognostication for pathologists?Amélie Bourhis, Caterina De Luca, Mélanie Cariou, et al.
Pathology|November 28, 2018
High reproducibility is attainable in assessing histoprognostic parameters of pT1 colorectal cancer using routine histopathology slides and immunohistochemistry analysesFanny Barel, Anaïs Auffret, Mélanie Cariou, et al.
Scientific Reports|June 8, 2019
Histopathological factors help to predict lymph node metastases more efficiently than extra-nodal recurrences in submucosa invading pT1 colorectal cancerFanny Barel, Mélanie Cariou, Philippe Saliou, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell LymphomaVincent Rebière, Meriem Maajem, Ronan Le Calloch, et al.
Pageof 2